AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA DHA
Number of subjects: 285
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 285
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nervonic acid (n-9 monounsaturated fatty acid)
Number of subjects: 285
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracosanoic acid (long-chain saturated fatty acid)
Number of subjects: 285
Study 28514000 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 169
Study 28514000 — intervention group
Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 169
Study 25472753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov external fixation (IE)
Number of subjects: 40
Study 25472753 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plate (PO)
Number of subjects: 40
Study 23871449 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 67
Study 23871449 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry reduction
Number of subjects: 67
Study 23871449 — intervention group
Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 67
Study 21741151 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted pelvic floor muscle training (APFMT) using Kegelmaster device
Number of subjects: 91
Study 21741151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 91
Study 18042413 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimetre wave therapy (MWT)
Number of subjects: 80
Study 18042413 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 80
Study 16819272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50
Study 16819272 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 50
Study 16819272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 50
Study 16819272 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50
Study 16819272 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study 12949688 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiated ethanol
Number of subjects: 0
Study 12949688 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiated morphine
Number of subjects: 0
Study 11041010 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated pattern of disconfirming information with processing instructions to focus on similarities
Number of subjects: 0
Study 11041010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersed pattern of disconfirming information with processing instructions to focus on similarities
Number of subjects: 0
Study 11041010 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing instructions to focus on differences
Number of subjects: 0
Study 11041010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific processing instructions)
Number of subjects: 0
Study 9310224 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/epi injectable gel (up to 2 cycles of ≤6 treatments)
Number of subjects: 22
Study 9310224 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/epi injectable gel (first cycle of treatment)
Number of subjects: 22
Study 8229537 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 15
Study 8229537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2872857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 37
Study 2872857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31410676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin composite (SAC) - Vertise Flow (VER)
Number of subjects: 27
Study 31410676 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin composite with self-etching adhesive - Filtek Z250 (Z250) / Clearfil SE Bond (CSEB)
Number of subjects: 27
Study 29750665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive distraction
Number of subjects: 213
Study 29750665 — intervention group
Group type: COMPARATOR
Intervention: Passive distraction
Number of subjects: 213
Study 29750665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive distraction with parent psychoeducation
Number of subjects: 213
Study 29750665 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction with parent psychoeducation
Number of subjects: 213
Study 27037050 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA + standard care (SC)
Number of subjects: 273
Study 27037050 — intervention group
Group type: COMPARATOR
Intervention: placebo + standard care (SC)
Number of subjects: 273
Study 24923421 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter volume (GMV) of the bilateral amygdala
Number of subjects: 264
Study 24923421 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval perception
Number of subjects: 264
Study 24923421 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter volume (GMV) of the bilateral temporal cortex
Number of subjects: 264
Study 24555229 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin (150 mg daily)
Number of subjects: 0
Study 24555229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml daily)
Number of subjects: 0
Study 24555229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg daily)
Number of subjects: 0
Study 24555229 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 21953329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg/h)
Number of subjects: 32
Study 21953329 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 32
Study 18296904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 29
Study 18296904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 29
Study 18296904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 29
Study 16567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (3 weekly doses starting at 34 weeks)
Number of subjects: 34
Study 16567174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal steroids (in cohort study)
Number of subjects: 34
Study 16567174 — intervention group
Group type: COMPARATOR
Intervention: No prenatal steroids (in cohort study)
Number of subjects: 34
Study 14653082 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (12 weeks treatment)
Number of subjects: 123
Study 14653082 — intervention group
Group type: COMPARATOR
Intervention: AT1-positive group
Number of subjects: 123
Study 14653082 — intervention group
Group type: COMPARATOR
Intervention: AT1-negative group
Number of subjects: 123
Study 11029563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36
Study 11029563 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study 9252833 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank analysis of covariance
Number of subjects: 0
Study 9252833 — intervention group
Group type: COMPARATOR
Intervention: Mantel-Haenszel procedure
Number of subjects: 0
Study 1376705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirating catheter
Number of subjects: 38
Study 1376705 — intervention group
Group type: COMPARATOR
Intervention: Standard perfusion catheter (infused group)
Number of subjects: 38
Study 3611779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic non-pharmacological methods
Number of subjects: 85
Study 31630347 — intervention group
Group type: EXPERIMENTAL
Intervention: SOVA web-based technology intervention
Number of subjects: 14
Study 31630347 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources provided to implement SOVA over 5 months
Number of subjects: 14
Study 31630347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey using EBPAS and PBS
Number of subjects: 14
Study 29853455 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-ON (tocilizumab + methotrexate)
Number of subjects: 105
Study 29853455 — intervention group
Group type: COMPARATOR
Intervention: SWITCH (tocilizumab alone)
Number of subjects: 105
Study 29853455 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with tocilizumab
Number of subjects: 105
Study 27906034 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused information on spirometry in the invitation
Number of subjects: 4356
Study 27906034 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation containing practical information
Number of subjects: 4356
Study 25098373 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program (3 sessions/week)
Number of subjects: 37
Study 25098373 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 37
Study 22416101 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transgastric necrosectomy
Number of subjects: 22
Study 22416101 — intervention group
Group type: COMPARATOR
Intervention: Surgical necrosectomy
Number of subjects: 22
Study 20035241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 2.5% phenylephrine (TP)
Number of subjects: 45
Study 20035241 — intervention group
Group type: COMPARATOR
Intervention: 1% tropicamide and 1% cyclopentolate (TC)
Number of subjects: 45
Study 17885779 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 22
Study 16967785 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mCi Iodine-131 (high dose)
Number of subjects: 40
Study 16967785 — intervention group
Group type: COMPARATOR
Intervention: 50 mCi Iodine-131 (low dose)
Number of subjects: 40
Study 14597947 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times per day)
Number of subjects: 16
Study 10523009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH-(1-24) stimulation tests (0.1, 0.5, and 1.0 microg/1.73 m2)
Number of subjects: 9
Study 10523009 — intervention group
Group type: COMPARATOR
Intervention: Insulin hypoglycemia test (0.15 U/kg insulin)
Number of subjects: 9
Study 10523009 — intervention group
Group type: COMPARATOR
Intervention: High dose ACTH stimulation test (250-microg ACTH-(1-24))
Number of subjects: 9
Study 10523009 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour ACTH-(1-24) infusion (250 microg at a constant rate over 8 h)
Number of subjects: 9
Study 7552477 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (500 mg/day)
Number of subjects: 135
Study 7552477 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (50, 300, or 1,000 mg daily)
Number of subjects: 135
Study 2048700 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 44
Study 2048700 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal intubation
Number of subjects: 44
Study 6108901 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (Catechin), 2 g/day
Number of subjects: 40
Study 6108901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30877308 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination during pregnancy
Number of subjects: 371
Study 30877308 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers not vaccinated during pregnancy)
Number of subjects: 371
Study 30561028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-aided instruction and practice on musculoskeletal anatomy
Number of subjects: 49
Study 30561028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound assistance during initial learning)
Number of subjects: 49
Study 27701902 — intervention group
Group type: COMPARATOR
Intervention: Reminder calls
Number of subjects: 201
Study 27701902 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 201
Study 24810252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 15
Study 23416015 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC ≤ 95 mg/l and NT-proBNP ≤ 32 pg/ml
Number of subjects: 68
Study 23416015 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 68
Study 23416015 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and LV diastolic diameter
Number of subjects: 68
Study 23416015 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan-4
Number of subjects: 68
Study 23416015 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC
Number of subjects: 68
Study 23525025 — intervention group
Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 195
Study 23525025 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg Alendronate weekly for eight weeks
Number of subjects: 195
Study 23525025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Alendronate daily for eight weeks
Number of subjects: 195
Study 19887957 — intervention group
Group type: COMPARATOR
Intervention: Coxibs
Number of subjects: 130541
Study 19887957 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 130541
Study 19887957 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib
Number of subjects: 130541
Study 16893712 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg warfarin initiation nomogram
Number of subjects: 50
Study 16893712 — intervention group
Group type: COMPARATOR
Intervention: 10 mg warfarin initiation nomogram
Number of subjects: 50
Study 15256610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 383
Study 15256610 — intervention group
Group type: EXPERIMENTAL
Intervention: Open drainage plus prednisolone
Number of subjects: 383
Study 11399987 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV voluntary counselling and testing (VCT)
Number of subjects: 0
Study 11399987 — intervention group
Group type: COMPARATOR
Intervention: Health information (HI)
Number of subjects: 0
Study 11399987 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive serostatus
Number of subjects: 0
Study 11399987 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of serostatus
Number of subjects: 0
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with current depression
Number of subjects: 559
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression and comorbid anxiety disorders
Number of subjects: 559
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (diurnal variation and suicidal tendencies)
Number of subjects: 559
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of appetite
Number of subjects: 559
Study 9438185 — intervention group
Group type: COMPARATOR
Intervention: Patients without mental disorders
Number of subjects: 559
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative overall health self-perception and severity of physical illness
Number of subjects: 559
Study 9438185 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability and reason for medical consultation
Number of subjects: 559
Study 8515827 — intervention group
Group type: EXPERIMENTAL
Intervention: Xantinolnicotinate
Number of subjects: 0
Study 8515827 — intervention group
Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 0
Study 3318546 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg body wt.)
Number of subjects: 50
Study 3318546 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 50
Study 3318546 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (1 mg/kg)
Number of subjects: 50
Study 3318546 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 50
Study 3318546 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 50
Study 28429883 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pamphlet on health and mood
Number of subjects: 140
Study 28429883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 140
Study 25811797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/social activities
Number of subjects: 221
Study 25811797 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activities
Number of subjects: 221
Study 24716641 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (mean daily dose)
Number of subjects: 203
Study 24716641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care unit length of stay
Number of subjects: 203
Study 23777947 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm bupivacaine
Number of subjects: 59
Study 23777947 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine at room temperature
Number of subjects: 59
Study 20850833 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (12 sessions, 30 minutes each, 3 times weekly)
Number of subjects: 35
Study 18847313 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (AMD3100) combined with G-CSF
Number of subjects: 0
Study 18847313 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 0
Study 17056965 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees reverse-Trendelenburg position
Number of subjects: 224
Study 17056965 — intervention group
Group type: COMPARATOR
Intervention: Horizontal tilt position (Control)
Number of subjects: 224
Study 12610195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg/d) during cisplatin chemotherapy
Number of subjects: 47
Study 12610195 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin chemotherapy alone
Number of subjects: 47
Study 10951428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomax(R) (Julphar, United Arab Emirates)
Number of subjects: 18
Study 10951428 — intervention group
Group type: COMPARATOR
Intervention: Maxaquin(R) (Searle, S.A., UK)
Number of subjects: 18
Study 8916958 — intervention group
Group type: EXPERIMENTAL
Intervention: International Index
Number of subjects: 242
Study 8916958 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative activity (% S-phase)
Number of subjects: 242
Study 8916958 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA aneuploidy
Number of subjects: 242
Study 8916958 — intervention group
Group type: EXPERIMENTAL
Intervention: Median % S-phase
Number of subjects: 242
Study 1897353 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 28
Study 1897353 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 28
Study 6412224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg three times daily
Number of subjects: 14
Study 6412224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and atenolol
Number of subjects: 14
Study 6412224 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 14
Study 6412224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30938089 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining using Buteyko breathing techniques
Number of subjects: 169
Study 28160272 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of antiretroviral therapy
Number of subjects: 85
Study 28160272 — intervention group
Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy
Number of subjects: 85
Study 26331791 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg racemic venlafaxine (VLX)
Number of subjects: 24
Study 24296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg)
Number of subjects: 30
Study 24296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 24296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 24296958 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine and Propofol
Number of subjects: 30
Study 22976533 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 20
Study 20154599 — intervention group
Group type: COMPARATOR
Intervention: Femoral catheterization
Number of subjects: 736
Study 20154599 — intervention group
Group type: COMPARATOR
Intervention: Jugular catheterization
Number of subjects: 736
Study 20154599 — intervention group
Group type: EXPERIMENTAL
Intervention: Right jugular position
Number of subjects: 736
Study 20154599 — intervention group
Group type: EXPERIMENTAL
Intervention: Left jugular position
Number of subjects: 736
Study 20154599 — intervention group
Group type: COMPARATOR
Intervention: Femoral site
Number of subjects: 736
Study 20154599 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular site
Number of subjects: 736
Study 20154599 — intervention group
Group type: COMPARATOR
Intervention: Both sites
Number of subjects: 736
Study 18606913 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT; 90% of Hfmax)
Number of subjects: 32
Study 18606913 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate exercise (CME; 70% of Hfmax)
Number of subjects: 32
Study 18606913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 15891811 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue (Tissucol) used for mesh fixation on the left side
Number of subjects: 55
Study 15891811 — intervention group
Group type: COMPARATOR
Intervention: Sutures (prolene 2/0) used for mesh fixation on the right side
Number of subjects: 55
Study 12408183 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine-restricted diet maintained after age 6
Number of subjects: 125
Study 12408183 — intervention group
Group type: COMPARATOR
Intervention: Diet discontinued after age 6
Number of subjects: 125
Study 9887236 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha plus ATRA (150 mg/m2/day orally in two divided doses)
Number of subjects: 63
Study 9887236 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha plus 13cRA (1 mg/kg/day orally)
Number of subjects: 63
Study 8005187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast potassium (TBX) 10 mg twice daily at 12 h intervals
Number of subjects: 7